309 related articles for article (PubMed ID: 21449627)
1. Brand name versus generic warfarin: a systematic review of the literature.
Dentali F; Donadini MP; Clark N; Crowther MA; Garcia D; Hylek E; Witt DM; Ageno W;
Pharmacotherapy; 2011 Apr; 31(4):386-93. PubMed ID: 21449627
[TBL] [Abstract][Full Text] [Related]
2. Are brand-name and generic warfarin interchangeable? Multiple n-of-1 randomized, crossover trials.
Pereira JA; Holbrook AM; Dolovich L; Goldsmith C; Thabane L; Douketis JD; Crowther MA; Bates SM; Ginsberg JS
Ann Pharmacother; 2005; 39(7-8):1188-93. PubMed ID: 15914517
[TBL] [Abstract][Full Text] [Related]
3. Observational cohort study of switching warfarin sodium products in a managed care organization.
Swenson CN; Fundak G
Am J Health Syst Pharm; 2000 Mar; 57(5):452-5. PubMed ID: 10711525
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of the switch from a branded to a generic warfarin sodium product: an observer-blinded, randomized, crossover study.
Lee HL; Kan CD; Yang YJ
Clin Ther; 2005 Mar; 27(3):309-19. PubMed ID: 15878384
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the clinical and economic impact of a brand name-to-generic warfarin sodium conversion program.
Witt DM; Tillman DJ; Evans CM; Plotkin TV; Sadler MA
Pharmacotherapy; 2003 Mar; 23(3):360-8. PubMed ID: 12627935
[TBL] [Abstract][Full Text] [Related]
6. Subtherapeutic INR values associated with a switch to generic warfarin.
Hope KA; Havrda DE
Ann Pharmacother; 2001 Feb; 35(2):183-7. PubMed ID: 11215837
[TBL] [Abstract][Full Text] [Related]
7. Trends in Hospital Visits for Generic and Brand-Name Warfarin Users in Québec, Canada: A Population-Based Time Series Analysis.
Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
Am J Cardiovasc Drugs; 2019 Jun; 19(3):287-297. PubMed ID: 30471054
[TBL] [Abstract][Full Text] [Related]
8. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs.
Borgheini G
Clin Ther; 2003 Jun; 25(6):1578-92. PubMed ID: 12860486
[TBL] [Abstract][Full Text] [Related]
9. Substitution of generic warfarin for Coumadin in an HMO setting.
Milligan PE; Banet GA; Waterman AD; Gatchel SK; Gage BF
Ann Pharmacother; 2002 May; 36(5):764-8. PubMed ID: 11978149
[TBL] [Abstract][Full Text] [Related]
10. Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching.
Halkin H; Shapiro J; Kurnik D; Loebstein R; Shalev V; Kokia E
Clin Pharmacol Ther; 2003 Sep; 74(3):215-21. PubMed ID: 12966365
[TBL] [Abstract][Full Text] [Related]
11. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis.
Kesselheim AS; Stedman MR; Bubrick EJ; Gagne JJ; Misono AS; Lee JL; Brookhart MA; Avorn J; Shrank WH
Drugs; 2010 Mar; 70(5):605-21. PubMed ID: 20329806
[TBL] [Abstract][Full Text] [Related]
12. Substituting warfarin products: what's the source of the problem?
Haines ST
Ann Pharmacother; 2011 Jun; 45(6):807-9. PubMed ID: 21666090
[TBL] [Abstract][Full Text] [Related]
13. Are brand-name and generic warfarin interchangeable? A survey of Ontario patients and physicians.
Pereira JA; Holbrook AM; Dolovich L; Goldsmith C; Thabane L; Douketis JD; Crowther M; Bates SM; Ginsberg JS
Can J Clin Pharmacol; 2005; 12(3):e229-39. PubMed ID: 16278495
[TBL] [Abstract][Full Text] [Related]
14. Design and rationale for the WARFA trial: a randomized controlled cross-over trial testing the therapeutic equivalence of branded and generic warfarin in atrial fibrillation patients in Brazil.
Freitas CG; Walsh M; Atallah ÁN
BMC Cardiovasc Disord; 2017 Jun; 17(1):148. PubMed ID: 28592234
[TBL] [Abstract][Full Text] [Related]
15. Generic switching of warfarin and risk of excessive anticoagulation: a Danish nationwide cohort study.
Hellfritzsch M; Rathe J; Stage TB; Thirstrup S; Grove EL; Damkier P; Pottegård A
Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):336-43. PubMed ID: 26696392
[TBL] [Abstract][Full Text] [Related]
16. Hemorrhagic and thrombotic events associated with generic substitution of warfarin in patients with atrial fibrillation: a retrospective analysis.
Ghate SR; Biskupiak JE; Ye X; Hagan M; Kwong WJ; Fox ES; Brixner DI
Ann Pharmacother; 2011 Jun; 45(6):701-12. PubMed ID: 21666081
[TBL] [Abstract][Full Text] [Related]
17. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.
Kwong WJ; Kamat S; Fang C
Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608
[TBL] [Abstract][Full Text] [Related]
18. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE
Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987
[TBL] [Abstract][Full Text] [Related]
19. Examining therapeutic equivalence between branded and generic warfarin in Brazil: The WARFA crossover randomized controlled trial.
Gomes Freitas C; Walsh M; Coutinho EL; Vincenzo de Paola AA; Atallah ÁN
PLoS One; 2021; 16(4):e0248567. PubMed ID: 33793580
[TBL] [Abstract][Full Text] [Related]
20. Epistaxis associated with elevation of INR in a patient switched to generic warfarin--another view.
Meibohm B; Zhang W; Beierle I; Meyer MC
Pharmacotherapy; 2000 Jul; 20(7):866-9; discussion 869-71. PubMed ID: 10907982
[No Abstract] [Full Text] [Related]
[Next] [New Search]
